Genflow Biosciences reports promising results for gene therapy in aged dogs, signalling potential breakthrough in age-related decline treatments

Genflow Biosciences’ SLAB trial demonstrates reductions in biological age in aged beagles, advancing the pursuit of SIRT6-based therapies for age-related decline amid cautious optimism.

Genflow Biosciences said its SLAB trial has met the main outcome measure in aged beagles, adding fresh momentum to its effort to develop SIRT6-based gene therapy for age-related decline.

The randomised, blinded study enrolled 24 beagles older than 10 years and split them into four arms: two naked-DNA dose groups, a single-dose AAV8 group and a saline control. According to the company, treated dogs recorded a reduction in biological age as measured by the GRIM methylation clock, alongside broader gains in functional and observable secondary measures.

The result extends interim findings reported earlier this year, when Genflow said the programme had shown encouraging muscle data and no safety issues. The company said detailed mechanistic and methylation-clock data will be presented at the Animal Longevity Summit in Toronto on 1-2 October 2026. It is also seeking Tier-1 animal health partners for licensing, co-development and eventual commercialisation.

For now, the read-through from a small canine study remains preliminary. But in a field that still lacks robust clinical proof, Genflow’s latest data offer a notable signal that its approach may have measurable biological effects.